Moreover, in melanoma tumors of the Gide2019 cohort, clinical advantages and therapeutic responses to PD-L1 and anti-CTLA4 blocking therapy were greater in patients with low SNAI2 expression (Figure 8F). The gene discussed is SNAI2; the disease is melanoma.